Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 13, Issue 9, Pages 1118-1126Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458507078916
Keywords
autoimmune; chelation; deferiprone; desferrioxamine; experimental allergic encephalomyelitis; iron; T cells
Categories
Funding
- NIA NIH HHS [AG23946] Funding Source: Medline
- NICHD NIH HHS [HD 02528] Funding Source: Medline
Ask authors/readers for more resources
The iron chelator, Desferal, suppressed disease activity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and it has been tested in pilot trials for MS. The administration regimen of Desferal is cumbersome and prone to complications. Orally-deliverable, iron chelators have been developed that circumvent these difficulties, and the objective of this study was to test an oral chelator in EAE. SJL mice with active EAE were randomly assigned to receive deferiprone (150 mg/kg) or vehicle (water) 2 x/day via gavage. EAE mice given deferiprone had significantly less disease activity and lower levels of inflammatory cell infiltrates (revealed by H&E staining) than EAE mice administered vehicle. T-cell infiltration, assessed by anti-CD3 immunohistochernical staining, also was reduced, although not significantly. Splenocytes cultured from naive SJL mice were stimulated with anti-CD3 and anti-CD28 with or without 250 mu M deferiprone. While similar to 39% of costimulated splenocytes without deferiprone underwent division, only similar to 2.8% of costimulated splenocytes with deferiprone divided and the latter cells were only 53% as viable as the former. Deferiprone had no effect on proliferation or viability of cells that were not costimulated. In summary, deferiprone effectively suppressed active EAE disease and it inhibited T-cell function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available